Real-Life Experience with Brentuximab Vedotin (Adcetris): the Belgian National Registry

This retrospective real-life survey support previously reported data on BV in terms of efficacy and toxicity. CR can be obtained in a short timeframe in a large proportion of CD30+ HL and sALCL patients. This therapeutic BV approach, used as a “bridge to transplant”, allows new promises in terms of cure in heavily pretreated CD30+lymphomas.